Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Purchases $12,800.00 in Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur bought 2,000 shares of the company’s stock in a transaction on Friday, May 10th. The stock was bought at an average price of $6.40 per share, with a total value of $12,800.00. Following the completion of the acquisition, the chief executive officer now owns 3,244,484 shares in the company, valued at $20,764,697.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Ron Bentsur also recently made the following trade(s):

• On Tuesday, May 14th, Ron Bentsur bought 1,940 shares of Nuvectis Pharma stock. The stock was bought at an average price of $6.74 per share, with a total value of $13,075.60.
• On Monday, March 18th, Ron Bentsur purchased 5,000 shares of Nuvectis Pharma stock. The shares were acquired at an average price of $10.29 per share, with a total value of $51,450.00.

Nuvectis Pharma Stock Performance

Shares of NASDAQ NVCT traded down $0.12 during mid-day trading on Thursday, reaching $6.65. 124,752 shares of the company’s stock were exchanged, compared to its average volume of 99,302. The company’s 50-day moving average is $7.80 and its 200-day moving average is $8.13. Nuvectis Pharma, Inc. has a 52-week low of $5.92 and a 52-week high of $18.65. The firm has a market capitalization of $122.09 million, a price-to-earnings ratio of -4.72 and a beta of 0.45.

Nuvectis Pharma (NASDAQ:NVCT) last announced its earnings results on Tuesday, March 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). As a group, equities analysts predict that Nuvectis Pharma, Inc. will post -1.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of Nuvectis Pharma in a report on Wednesday, May 8th.

Hedge Funds Weigh In On Nuvectis Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Strs Ohio raised its position in Nuvectis Pharma by 178.6% in the 3rd quarter. Strs Ohio now owns 3,900 shares of the company’s stock valued at $50,000 after purchasing an additional 2,500 shares in the last quarter. Baldwin Brothers LLC MA raised its position in Nuvectis Pharma by 22.0% in the 4th quarter. Baldwin Brothers LLC MA now owns 142,040 shares of the company’s stock valued at $1,185,000 after purchasing an additional 25,660 shares in the last quarter. Edmond DE Rothschild Holding S.A. acquired a new stake in Nuvectis Pharma in the 4th quarter valued at about $160,000. Blue Zone Wealth Advisors LLC acquired a new stake in Nuvectis Pharma in the 1st quarter valued at about $118,000. Finally, Vanguard Group Inc. raised its position in Nuvectis Pharma by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 298,800 shares of the company’s stock valued at $2,450,000 after purchasing an additional 4,517 shares in the last quarter. 96.77% of the stock is currently owned by hedge funds and other institutional investors.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.